文献速递特殊人群用药药物不良反应与药物警戒

精准医学在儿童肥胖识别、预防和治疗中的应用

Precision medicine to identify, prevent, and treat pediatric obesity.
PubMed 文献 · Pharmacotherapy · 2024-11-16

本文为叙述性综述,聚焦儿童肥胖遗传学三方面:易感基因、可预测药物相关体重增加的药物基因组学、抗肥胖药物的药物基因组学。综述评估遗传病因如何优化药物治疗以减少体重增加并改善肥胖治疗,指出多种肥胖遗传病因已有或正在出现靶向基因治疗,但药物基因组学指导避免体重增加尚无临床指南。

要点

  • 儿童肥胖含基因组肥胖综合征和单基因肥胖障碍等多种遗传病因。
  • 抗精神病药、抗癫痫药、抗抑郁药和类固醇相关体重增加的药物基因组学靶点已识别,但尚无临床应用指南。
  • 基因检测覆盖立法与技术进展将降低成本并扩大可及性,推动精准医学指南制定。

核心结论

  • 精准医学可用于识别儿童肥胖遗传病因并优化药物治疗以减少药物相关体重增加。
  • 多种肥胖遗传病因已有或正在出现靶向基因治疗。
  • 药物基因组学指导避免体重增加尚无临床指南,需进一步研究制定。

研究设计与样本

  • 叙述性综述,评估儿童肥胖遗传病因及遗传发现如何优化药物治疗。

主要发现

  • 儿童肥胖有多种遗传病因,包括基因组肥胖综合征和单基因肥胖障碍。
  • 抗精神病药、抗癫痫药、抗抑郁药和类固醇相关体重增加的药物基因组学靶点已识别。
  • 目前尚无临床应用药物基因组学指导药物治疗以避免体重增加的临床指南。

临床怎么用

  • 可考虑遗传评估识别儿童肥胖遗传病因以指导靶向治疗。
  • 对使用抗精神病药、抗癫痫药、抗抑郁药或类固醇的患儿,关注药物基因组学靶点以评估体重增加风险。
  • 基因检测成本降低和可及性扩大将促进精准医学在儿童肥胖管理中的应用。

局限性

  • 本文为叙述性综述,未报告系统检索范围。
  • 药物基因组学指导避免体重增加尚无临床指南,临床应用证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pediatric obesity is a growing health concern that has many secondary adverse health implications. Personalized medicine is a tool that can be used to optimize diagnosis and treatments of many diseases. In this review, we will focus on three areas related to the genetics of pediatric obesity: (i) genetic causes predisposing to pediatric obesity, (ii) pharmacogenomics that may predict weight gain associated with pharmacotherapy, and (iii) pharmacogenomics of anti-obesity pharmacotherapy. This narrative review evaluates genetic cause of pediatric obesity and how genetic findings can be used to optimize pharmacotherapy to minimize weight gain and optimize obesity treatment in pediatric patients. Pediatric obesity has many genetic causes including genomic obesity syndromes and monogenic obesity disorders. Several genetic etiologies of obesity have current or emerging targeted genetic therapies. Pharmacogenomic (PGx) targets associated with pharmacotherapy-induced weight gain have been identified for antipsychotic, antiepileptic, antidepressant therapies, and steroids, yet to date no clinical guidelines exist for application use of PGx to tailor pharmacotherapy to avoid weight gain. As legislation evolves for genetic testing coverage and technology advances, this will decrease cost and expand access to genetic testing. This will result in identification of potential genetic causes of obesity and genes that predispose to pharmacotherapy-induced weight gain. Advances in precision medicine can ultimately lead to development of clinical practice guidelines on how to apply genetic findings to optimize pharmacotherapy to treat genetic targets of obesity and avoid weight gain as an adverse event associated with pharmacotherapy.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Tillman EM, Mertami S. Precision medicine to identify, prevent, and treat pediatric obesity. Pharmacotherapy. 2024. PMID: 39548737. doi:10.1002/phar.4626

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。